Evidence map›Paper›PMID 39763602›Full record

ArticleFrontiers in oncology2024

Penpulimab and Anlotinib in PDL1 high-expression pulmonary giant cell carcinoma with cerebral metastases: case report and review.

Minghong Xie, Yunlong Zhao, Xiaohua Hou, Ning Li, Sha Niu, Xinju Xu

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Minghong XieDepartment of Respiratory and Critical Care Medicine, First Affiliated Hospital of Henan Polytechnic University, Jiaozuo Second People's Hospital, Jiaozuo, China.
Yunlong ZhaoDepartment of Pathology, First Affiliated Hospital of Henan Polytechnic University, Jiaozuo Second People's Hospital, Jiaozuo, Henan, China.
Xiaohua HouDepartment of Respiratory and Critical Care Medicine, First Affiliated Hospital of Henan Polytechnic University, Jiaozuo Second People's Hospital, Jiaozuo, China.
Ning LiDepartment of Respiratory and Critical Care Medicine, First Affiliated Hospital of Henan Polytechnic University, Jiaozuo Second People's Hospital, Jiaozuo, China.
Sha NiuDepartment of Respiratory and Critical Care Medicine, First Affiliated Hospital of Henan Polytechnic University, Jiaozuo Second People's Hospital, Jiaozuo, China.
Xinju XuDepartment of Respiratory and Critical Care Medicine, First Affiliated Hospital of Henan Polytechnic University, Jiaozuo Second People's Hospital, Jiaozuo, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pulmonary giant cell carcinoma (PGCC) is a rare subtype of non-small cell lung cancer (NSCLC) characterized by complex pathology, high rates of misdiagnosis or missed diagnosis, an aggressive clinical course, rapid progression, and poor prognosis. This case report describes a 67-year-old Chinese male with a left upper lobe lung mass, diagnosed

Indexed as

Anlotinibcerebral metastasesPD-L1 positivityPenpulimab injectionpulmonary giant cell carcinoma

Identifiers

PMID39763602
PMCPMC11700828

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.